Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS^G12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.

ABSTRACT: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) and untreated CNS metastases have a worse prognosis than similar patients without KRAS mutations. Adagrasib has previously demonstrated CNS penetration preclinically and cerebral spinal fluid penetration clinically. We evaluated adagrasib in p

SUBMITTER: Negrao MV 

PROVIDER: S-EPMC10553074 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature